| 0 (0%) | 09-15 13:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 655.65  |
1-year : | 699.5 |
| Resists | First : | 561.34 |
Second : | 598.89 |
| Pivot price | 531.93 |
|||
| Supports | First : | 500.6 | Second : | 416.5 |
| MAs | MA(5) : | 509.94 |
MA(20) : | 537.84 |
| MA(100) : | 554.84 |
MA(250) : | 612.92 |
|
| MACD | MACD : | -13.8  |
Signal : | -10.4 |
| %K %D | K(14,3) : | 14.3 |
D(3) : | 9.1 |
| RSI | RSI(14): 37.2 |
|||
| 52-week | High : | 769.97 | Low : | 500.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IDXX ] has closed above bottom band by 25.1%. Bollinger Bands are 47.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 516.68 - 520.1 | 520.1 - 523.2 |
| Low: | 497.47 - 501.88 | 501.88 - 505.86 |
| Close: | 502.83 - 509.69 | 509.69 - 515.89 |
Mon, 14 Sep 2026
IDXX: Innovation and commercial expansion drive recurring revenue growth and higher diagnostic utilization - TradingView
Mon, 14 Sep 2026
IDXX: Innovation-driven growth and rising diagnostic utilization fuel robust financial and margin outlook - TradingView
Mon, 14 Sep 2026
IDXX: Innovation and recurring revenue drive strong growth, with new diagnostics expanding global adoption - TradingView
Sun, 13 Sep 2026
IDEXX Laboratories (IDXX) Keeps Growing, Is The Stock Still A Bargain? - simplywall.st
Fri, 11 Sep 2026
IDXX - Finviz
Wed, 09 Sep 2026
IDEXX Laboratories (IDXX) director exercises options and sells 2,203 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 79 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 96.8 (%) |
| Shares Short | 1,940 (K) |
| Shares Short P.Month | 2,100 (K) |
| EPS | 14.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.44 |
| Profit Margin | 25 % |
| Operating Margin | 34.9 % |
| Return on Assets (ttm) | 27 % |
| Return on Equity (ttm) | 74.2 % |
| Qtrly Rev. Growth | 9.6 % |
| Gross Profit (p.s.) | 36.04 |
| Sales Per Share | 57.75 |
| EBITDA (p.s.) | 20.56 |
| Qtrly Earnings Growth | 17.6 % |
| Operating Cash Flow | 1,370 (M) |
| Levered Free Cash Flow | 909 (M) |
| PE Ratio | 36.08 |
| PEG Ratio | 2.9 |
| Price to Book value | 25.13 |
| Price to Sales | 8.89 |
| Price to Cash Flow | 29.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|